Market Overview:
The global neurometabolic disorders market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of neurometabolic disorders, rising awareness about these diseases, and technological advancements in the field of diagnostics and treatment. In terms of application, the market is divided into oral and parenteral applications. Parenteral application dominated the global neurometabolic disorders market in 2017 owing to better patient compliance rates for this mode of administration as compared to oral administration. Geographically, the global neurometabolic disorders market is segmented into North America, Latin America Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
Neurometabolic Disorders are a group of rare genetic disorders that affect the brain and nervous system. They can cause problems with movement, learning, thinking, and other basic functions. Most neurometabolic disorders are passed down in families. Some can be caused by a mistake in the genes that are passed down from parents to their children (mutations). Many of these disorders lead to serious health problems and early death if not treated.
Gaucher’s Disease:
Gaucher's disease is a rare genetic disorder that affects the body's immune system and leads to progressive damage of the small intestine. The disease is named after Dr. Maximilian Gaucher, who first described it in 1867. There are two types of gaucher's disease: early-onset (EO) and late-onset (LO).
Fabry Disease:
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase enzyme resulting in progressive organ dysfunction. The most commonly affected organs are the eyes, skin, gastrointestinal system and heart. Fabry patients also show neurological complications which may include stroke myelopathy, cerebrovascular accident or multiple sclerosis later in life as well as during treatment with certain drugs (e.g., penicillin).
Application Insights:
Parenteral drugs are used for the treatment of various diseases such as cancer, HIV, and diabetes. The demand for parenteral drugs is expected to witness a rise in the coming years owing to its high therapeutic value and low bio-distribution rate. In addition, factors such as increasing incidences of chronic diseases that require long term medication along with an increase in geriatric population susceptible to these disorders are anticipated to drive segment growth during the forecast period.
The oral application segment held around 40% share of global revenue in 2017 due to presence of numerous products available in the market for neurological disorders that target specific symptoms associated with neurodegenerative conditions.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of patients suffering from neuro metabolic disorders, increasing awareness about these conditions, availability of effective treatment methods and supportive government initiatives. Moreover, an increase in healthcare expenditure by private as well as public sectors is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure and rising prevalence of diabetes & obesity which are leading causes for neurodegenerative diseases such as Parkinson’s disease (PD) and Huntington’s disease (HD). In addition, growing disposable income levels coupled with increased adoption of western culture & lifestyle will further propel regional market growth during the estimated time span.
Growth Factors:
- Increasing incidence of neurological disorders and metabolic diseases
- Growing awareness about the early diagnosis and treatment of neurometabolic disorders
- Rising prevalence of lifestyle-associated diseases such as obesity, diabetes, and hypertension
- Technological advancements in the field of neurology and metabolic research
- Growing demand for novel therapeutics for the treatment of neurometabolic disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Neurometabolic Disorders Market Research Report
By Type
Gaucher’s Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis VI, Other
By Application
Oral, Parenteral
By Companies
Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation, Lixte Biotechnology, Neuraltus Pharmaceuticals, Protalix, Pharming Group, Protalix BioTherapeutics, Amicus, Biomarin, Genzyme, Shire, Greencross
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Neurometabolic Disorders Market Report Segments:
The global Neurometabolic Disorders market is segmented on the basis of:
Types
Gaucher’s Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis VI, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oral, Parenteral
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amicus Therapeutics
- ISU Abxis
- JCR Pharmaceuticals
- Biosidus
- Greenovation Biotech
- UAB Proforma
- Dong-A Socio Group
- ExSAR Corporation
- Lixte Biotechnology
- Neuraltus Pharmaceuticals
- Protalix
- Pharming Group
- Protalix BioTherapeutics
- Amicus
- Biomarin
- Genzyme
- Shire
- Greencross
Highlights of The Neurometabolic Disorders Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gaucher’s Disease
- Fabry Disease
- Pompe Disease
- Mucopolysaccharidosis VI
- Other
- By Application:
- Oral
- Parenteral
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neurometabolic Disorders Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neurometabolic disorders are a group of conditions that affect the nervous system. These disorders can cause problems with brain function, including problems with memory, thinking, and coordination. They can also lead to changes in mood and behavior.
Some of the major players in the neurometabolic disorders market are Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation, Lixte Biotechnology, Neuraltus Pharmaceuticals, Protalix, Pharming Group, Protalix BioTherapeutics, Amicus, Biomarin, Genzyme, Shire, Greencross.
The neurometabolic disorders market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neurometabolic Disorders Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neurometabolic Disorders Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neurometabolic Disorders Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neurometabolic Disorders Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neurometabolic Disorders Market Size & Forecast, 2018-2028
4.5.1 Neurometabolic Disorders Market Size and Y-o-Y Growth
4.5.2 Neurometabolic Disorders Market Absolute $ Opportunity
Chapter 5 Global Neurometabolic Disorders Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Neurometabolic Disorders Market Size Forecast by Type
5.2.1 Gaucher’s Disease
5.2.2 Fabry Disease
5.2.3 Pompe Disease
5.2.4 Mucopolysaccharidosis VI
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Neurometabolic Disorders Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Neurometabolic Disorders Market Size Forecast by Applications
6.2.1 Oral
6.2.2 Parenteral
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neurometabolic Disorders Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neurometabolic Disorders Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neurometabolic Disorders Analysis and Forecast
9.1 Introduction
9.2 North America Neurometabolic Disorders Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neurometabolic Disorders Market Size Forecast by Type
9.6.1 Gaucher’s Disease
9.6.2 Fabry Disease
9.6.3 Pompe Disease
9.6.4 Mucopolysaccharidosis VI
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Neurometabolic Disorders Market Size Forecast by Applications
9.10.1 Oral
9.10.2 Parenteral
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Neurometabolic Disorders Analysis and Forecast
10.1 Introduction
10.2 Europe Neurometabolic Disorders Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neurometabolic Disorders Market Size Forecast by Type
10.6.1 Gaucher’s Disease
10.6.2 Fabry Disease
10.6.3 Pompe Disease
10.6.4 Mucopolysaccharidosis VI
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Neurometabolic Disorders Market Size Forecast by Applications
10.10.1 Oral
10.10.2 Parenteral
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Neurometabolic Disorders Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neurometabolic Disorders Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neurometabolic Disorders Market Size Forecast by Type
11.6.1 Gaucher’s Disease
11.6.2 Fabry Disease
11.6.3 Pompe Disease
11.6.4 Mucopolysaccharidosis VI
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Neurometabolic Disorders Market Size Forecast by Applications
11.10.1 Oral
11.10.2 Parenteral
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Neurometabolic Disorders Analysis and Forecast
12.1 Introduction
12.2 Latin America Neurometabolic Disorders Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neurometabolic Disorders Market Size Forecast by Type
12.6.1 Gaucher’s Disease
12.6.2 Fabry Disease
12.6.3 Pompe Disease
12.6.4 Mucopolysaccharidosis VI
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Neurometabolic Disorders Market Size Forecast by Applications
12.10.1 Oral
12.10.2 Parenteral
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Neurometabolic Disorders Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neurometabolic Disorders Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neurometabolic Disorders Market Size Forecast by Type
13.6.1 Gaucher’s Disease
13.6.2 Fabry Disease
13.6.3 Pompe Disease
13.6.4 Mucopolysaccharidosis VI
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Neurometabolic Disorders Market Size Forecast by Applications
13.10.1 Oral
13.10.2 Parenteral
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neurometabolic Disorders Market: Competitive Dashboard
14.2 Global Neurometabolic Disorders Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amicus Therapeutics
14.3.2 ISU Abxis
14.3.3 JCR Pharmaceuticals
14.3.4 Biosidus
14.3.5 Greenovation Biotech
14.3.6 UAB Proforma
14.3.7 Dong-A Socio Group
14.3.8 ExSAR Corporation
14.3.9 Lixte Biotechnology
14.3.10 Neuraltus Pharmaceuticals
14.3.11 Protalix
14.3.12 Pharming Group
14.3.13 Protalix BioTherapeutics
14.3.14 Amicus
14.3.15 Biomarin
14.3.16 Genzyme
14.3.17 Shire
14.3.18 Greencross
